Loading stock data…
SRZN
$33.60+0.20 (+0.60%)
Market ClosedLast close May 1
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Surrozen, Inc. in the Healthcare sector is trading at $33.60. The stock is currently near its 52-week high of $35.00, remaining 79.9% above its 200-day moving average. Technical signals show neutral RSI of 60 and bullish MACD crossover, explaining why SRZN maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$33.60
Potential Upside
5%
Whystock Fair Value$35.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseas...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$388.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
128.90%
Volume
Today's trading volume
62,047
Recent News
Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?
Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Surrozen Conference: CEO Details Wnt-Fzd4 Eye Disease Bet, 2026 IND Plans for SZN-8141
Surrozen (NASDAQ:SRZN) Chief Executive Officer Craig Parker used a discussion at a 2026 investor summit to outline the company’s focus on Wnt pathway biology and antibody engineering, with an emphasis on retinal vascular diseases. Parker said Surrozen has worked on Wnt signaling since its founding i
We're Hopeful That Surrozen (NASDAQ:SRZN) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Surrozen...
Institutions own 32% of Surrozen, Inc. (NASDAQ:SRZN) shares but private equity firms control 32% of the company
Key Insights Surrozen's significant private equity firms ownership suggests that the key decisions are influenced by...